Riverbridge Partners LLC Sells 16,654 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Riverbridge Partners LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 7.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 222,734 shares of the medical research company's stock after selling 16,654 shares during the quarter. Riverbridge Partners LLC owned 0.45% of Charles River Laboratories International worth $33,526,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Janney Montgomery Scott LLC boosted its stake in Charles River Laboratories International by 13.1% in the first quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock worth $6,698,000 after buying an additional 5,148 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Charles River Laboratories International by 61.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock worth $84,000 after acquiring an additional 175 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $335,000. Asset Management One Co. Ltd. raised its stake in shares of Charles River Laboratories International by 1.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 18,918 shares of the medical research company's stock worth $3,522,000 after acquiring an additional 315 shares in the last quarter. Finally, M.D. Sass LLC raised its stake in shares of Charles River Laboratories International by 22.0% during the fourth quarter. M.D. Sass LLC now owns 391,824 shares of the medical research company's stock worth $72,331,000 after acquiring an additional 70,652 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Down 0.0%

Shares of NYSE CRL traded down $0.04 during mid-day trading on Monday, hitting $147.41. The stock had a trading volume of 1,487,949 shares, compared to its average volume of 1,015,487. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The business has a 50 day moving average price of $132.56 and a two-hundred day moving average price of $154.70. The firm has a market cap of $7.24 billion, a P/E ratio of -226.79, a price-to-earnings-growth ratio of 4.55 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period in the previous year, the firm earned $2.27 EPS. The company's quarterly revenue was down 2.7% compared to the same quarter last year. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on CRL shares. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Barclays lifted their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. Finally, Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).